Catalog3 refs
Orforglipron (LY-3502970)
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Oral small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks. 79.1% oral bioavailability.
Primary Uses
Weight loss (obesity without diabetes)
Weight loss (obesity with type 2 diabetes)
Type 2 diabetes management
Insulin resistance improvement
Cardiometabolic risk reduction
Prediabetes prevention
Protocol Reference
Dose
Start 3-6mg daily, titrate up to 12-36mg based on response
Frequency
Once daily
Half-life
25-68 hours
Route
Oral tablet
Evidence
Extensively Studied
Research Models
Human
Also in Metabolic